CABLIVI caplacizumab

Drug Class

von Willebrand factor (vWF)-directed antibody fragment

Mechanism

Caplacizumab binds to the A1 domain of von Willebrand factor (vWF), blocking its interaction with platelet GP Ib-IX-V receptors and preventing microvascular thrombosis.

Approved Indication

Treatment of adults and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

What This Means For Patients

CABLIVI is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2019) — Sources
• EMA — Approved (2018) — Sources
• NMPA — Approved (2025) — Sources

Pivotal Clinical Evidence

• HERCULES — Scully et al., N Engl J Med 2019 (NCT02553317) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761107s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi
• https://doi.org/10.1056/NEJMoa1806311